Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lupus Nephritis × Etanercept × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Arthritis, Rheumatoid 16 Psoriasis 7 Leukemia 5 Lymphoma, Follicular 4 Spondylitis, Ankylosing 3 Myelodysplastic Syndromes 3 Inflammation 3 Asthma 3 Arthritis, Juvenile 3 Vasculitis 2 Uveitis 2 Respiratory Distress Syndrome 2 Recurrence 2 Prostatic Neoplasms 2 Pneumonia 2 Neuroblastoma 2 Neoplasms 2 Myeloproliferative Disorders 2 Myelodysplastic-Myeloproliferative Diseases 2 Leukemia, Myelomonocytic, Juvenile 2 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2 Granulomatosis with Polyangiitis 2 Bronchiolitis Obliterans 2 Arthritis, Psoriatic 2 Wilms Tumor 1 Temporomandibular Joint Disorders 1 Stomatitis 1 Spondylarthritis 1 Pruritus 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00447265 2013-02-12

Etanercept for the Treatment of Lupus Nephritis

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 2 Terminated

1 enrolled 15 charts

Lupus Nephritis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡